<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Psyence Biomedical Ltd. Common Shares — News on 6ix</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares</link>
<description>Latest news and press releases for Psyence Biomedical Ltd. Common Shares on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/psyence-biomedical-ltd-common-shares" rel="self" type="application/rss+xml" />
<item>
<title>Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-initiates-patient-dosing-in-phase-iib-trial-evaluating-npx-5-for-adjustment-disorder</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-initiates-patient-dosing-in-phase-iib-trial-evaluating-npx-5-for-adjustment-disorder</guid>
<pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
<description>Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site networkNEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for</description>
</item>
<item>
<title>Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-positioned-as-worlds-only-licensed-pharmaceutical-grade-ibogaine-supplier-at-source</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-positioned-as-worlds-only-licensed-pharmaceutical-grade-ibogaine-supplier-at-source</guid>
<pubDate>Mon, 20 Apr 2026 04:00:00 GMT</pubDate>
<description>Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain NEW YORK, April 20,</description>
</item>
<item>
<title>Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-welcomes-us-executive-action-to-advance-research-into-ibogaine</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-welcomes-us-executive-action-to-advance-research-into-ibogaine</guid>
<pubDate>Fri, 17 Apr 2026 13:15:00 GMT</pubDate>
<description>Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supplyNEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a n</description>
</item>
<item>
<title>Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV Agreement</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/pacific-bay-and-aurwest-sign-weaver-gold-property-definitive-optionjv-agreement-1</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/pacific-bay-and-aurwest-sign-weaver-gold-property-definitive-optionjv-agreement-1</guid>
<pubDate>Tue, 14 Apr 2026 17:17:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Pacific Bay Minerals Ltd. (TSXV: PBM) ("Pacific Bay" or the "Company") reports that the Company has entered into a definitive option and joint venture agreement (the "Agreement") with Aurwest Resources Corporation (CSE: AWR) whereby Aurwest has acquired an option to earn, subject to the satisfaction of conditions, an undivided interest of up to 50% in Pacific Bay's Weaver Gold gold/silver property (the "Transaction") in British...</description>
</item>
<item>
<title>Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-expands-australian-clinical-site-network-to-five-sites-advancing-npx-5-supported-clinical-activities</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-expands-australian-clinical-site-network-to-five-sites-advancing-npx-5-supported-clinical-activities</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Expansion supports accelerated enrollment and advancement of the Company’s lead clinical asset NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical</description>
</item>
<item>
<title>Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/corporate-update-psyence-biomed-advances-vertically-integrated-pharmaceutical-platform-following-psylabs-export-milestone-2</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/corporate-update-psyence-biomed-advances-vertically-integrated-pharmaceutical-platform-following-psylabs-export-milestone-2</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>“The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig NEW YORK, March 11, 2026 (GLOBE</description>
</item>
<item>
<title>Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-export-of-gmp-manufactured-natural-psilocybin-npx-5-to-australia-for-ongoing-phase-iib-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-export-of-gmp-manufactured-natural-psilocybin-npx-5-to-australia-for-ongoing-phase-iib-clinical-trial</guid>
<pubDate>Tue, 03 Mar 2026 14:15:00 GMT</pubDate>
<description>NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the successful export of fully GMP-compliant manufactured psilocybin product NPX-5 (1mg and 5mg capsules) to Australia. The product was manufactured at the Psyence Labs Ltd. (“PsyLabs”) GMP-controlled production facility, supporting pharmaceutica</description>
</item>
<item>
<title>Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-exercise-of-put-option-by-psylabs-and-strategic-equity-investment</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-exercise-of-put-option-by-psylabs-and-strategic-equity-investment</guid>
<pubDate>Fri, 20 Feb 2026 22:20:00 GMT</pubDate>
<description>NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds ("PsyLabs") has exercised its rights under a previously disclosed put option agreement (the "Put Option Agreement"), pursuant to which Psyen</description>
</item>
<item>
<title>Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-results-annual-141500713</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-results-annual-141500713</guid>
<pubDate>Tue, 17 Feb 2026 14:15:00 GMT</pubDate>
<description>NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election o</description>
</item>
<item>
<title>Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-approves-put-option-233000194</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-approves-put-option-233000194</guid>
<pubDate>Fri, 13 Feb 2026 23:30:00 GMT</pubDate>
<description>The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby securing predictable and reliable supply of pharmaceutical grade psychedelics, as the pathway to commercialization unfoldsNEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin</description>
</item>
<item>
<title>Psyence BioMed Announces Settlement of Shareholder Litigation</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-settlement-shareholder-141500712</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-settlement-shareholder-141500712</guid>
<pubDate>Wed, 11 Feb 2026 14:15:00 GMT</pubDate>
<description>NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd ("KAOS"). The claim, originally made on January 14, 2026, and amplified on January 26, 2026, alleged, among other things, improper and oppressive actions on the part of the Company against KAOS, resulting in KAOS suffering alleged damages (the "KAOS Alleg</description>
</item>
<item>
<title>Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-effective-date-233000870</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-effective-date-233000870</guid>
<pubDate>Wed, 28 Jan 2026 23:30:00 GMT</pubDate>
<description>NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026, however, following further</description>
</item>
<item>
<title>Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-adjournment-annual-184200417</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-adjournment-annual-184200417</guid>
<pubDate>Thu, 22 Jan 2026 18:42:00 GMT</pubDate>
<description>NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders (the “Meeting”) until February 12, 2026. The Meeting will now be held on February 12, 2026, at 9:00 a.m. New York Time/4:00 p.m. Cape Town time at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935, South Africa. The adjournment is a result of</description>
</item>
<item>
<title>Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-postponement-previously-121900148</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-postponement-previously-121900148</guid>
<pubDate>Tue, 20 Jan 2026 12:19:00 GMT</pubDate>
<description>NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock. As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026. Followin</description>
</item>
<item>
<title>Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-approves-2026-financial-133000029</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-approves-2026-financial-133000029</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions. T</description>
</item>
<item>
<title>Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-achieves-milestone-natural-141500229</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-achieves-milestone-natural-141500229</guid>
<pubDate>Mon, 05 Jan 2026 14:15:00 GMT</pubDate>
<description>NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a natural</description>
</item>
<item>
<title>Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-approval-psylabs-120000015</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-approval-psylabs-120000015</guid>
<pubDate>Fri, 19 Dec 2025 12:00:00 GMT</pubDate>
<description>With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trialsNEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that the Bellberry Human Research Ethics Committee (HREC) has</description>
</item>
<item>
<title>Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-ceo-letter-highlights-120000551</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-ceo-letter-highlights-120000551</guid>
<pubDate>Tue, 09 Dec 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today released a year-end Letter from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026. In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which</description>
</item>
<item>
<title>Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-groundbreaking-psilocybin-120000971</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-announces-groundbreaking-psilocybin-120000971</guid>
<pubDate>Tue, 25 Nov 2025 12:00:00 GMT</pubDate>
<description>First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence</description>
</item>
<item>
<title>Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets</title>
<link>https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-reaches-major-breakthrough-120000195</link>
<guid isPermaLink="true">https://6ix.com/company/psyence-biomedical-ltd-common-shares/news/psyence-biomed-reaches-major-breakthrough-120000195</guid>
<pubDate>Thu, 20 Nov 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs. This is a significant achievement for the Company</description>
</item>
</channel>
</rss>